Novo Nordisk invests $2.3bn in new Danish multiproduct API facility

Published: 13-Jun-2023

The Denmark-based pharma expert has announced the new 65,000 sqm facility, which will be designed with maximum flexibility to accommodate new processes and display state-of-the-art technology and working environment

Novo Nordisk has announced plans to invest 15.9 billion Danish kroner ($2.3bn) starting in 20231 to expand an existing Active Pharmaceutical Ingredient (API) production facility in Denmark for the future portfolio within serious chronic diseases.

The investment comes as Novo Nordisk marks the 100th anniversary of its founding in Denmark, where 21,000-plus employees – approximately half of the company's global workforce - still work today. The majority of these employees work at various production sites.

I would like to take this opportunity to thank the Danish Government and Parliament for their continued focus on ensuring good and stable infrastructure and supplies

- Henrik Wulff, Executive VP of Product Supply, Quality & IT

The investment in Hillerød, Denmark will create additional production capacity and increase Novo Nordisk’s ability to meet future market demands and be a key enabler for Novo Nordisk to develop its future clinical late-phase product portfolio.

“This important investment will ensure the continuous development of our late-phase pipeline into deliveries of important medicines for treatments to patients worldwide,” said Henrik Wulff, Executive VP of Product Supply, Quality & IT. “The investment announced today confirms Hillerød and Denmark as cornerstones in our global footprint, and I would like to take this opportunity to thank the Danish Government and Parliament for their continued focus on ensuring good and stable infrastructure and supplies – allowing us to continue to expand our production capacity to the benefit of patients living with serious chronic diseases."

Like this story? Subscribe to Cleanroom Technology magazine for incisive analysis of the latest news and developments in hi-tech industries manufacturing in controlled environments.

The new facility – which will be approximately 65,000 sqm – will be designed as a multi-product facility, with maximum flexibility to accommodate new processes and displaying state-of-the-art technology and working environment.

As a future-proof and cost-effective facility, the construction will focus on delivering the highest quality to patients worldwide in an efficient and environmentally sustainable way. This will be done by designing optimal and compact process flows allowing a substantial reduction of water and energy consumption.

Construction is underway and the facility is expected to start producing API by early 2029. This project is expected to create 340 new jobs when construction is completed, and the facility is fully equipped.

You may also like